Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...